Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 2/20 | 0.52 |
| ▸ | TPI1 | P60174 | 1/20 | 0.52 |
| ▸ | CASP6 | P55212 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | HTR1E | P28566 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1945866 | 0.77 | MAPT (0.61) | ALDH1A1KMT2AMAPTSMN1; SMN2GLA | |
| SCHEMBL1546582 | 0.76 | MAPT (0.59) | CDK1TPI1CDK4CDK2ALDH1A1 | |
| SCHEMBL1945572 | 0.76 | CDK1 (0.38) | CDK1TPI1CASP6CDK4CDK2 | |
| SCHEMBL1947204 | 0.74 | MAPT (0.63) | ALDH1A1KMT2AMAPTSMN1; SMN2GLA | |
| SCHEMBL1546631 | 0.74 | EPHX2 (0.52) | CDK1TPI1EPHX2GFERALDH1A1 | |
| SCHEMBL1947363 | 0.73 | CDK1 (0.39) | CDK1TPI1CASP6CDK4CDK2 | |
| SCHEMBL1712992 | 0.73 | MAPT (0.57) | ALDH1A1KMT2ARAB9AMAPTSMN1; SMN2 | |
| SCHEMBL1945858 | 0.73 | MEN1 (0.51) | ALDH1A1KMT2AMAPTSMN1; SMN2GLA | |
| SCHEMBL15667389 | 0.72 | EPHX2 (0.50) | CDK1TPI1EPHX2GFERALDH1A1 | |
| SCHEMBL1946777 | 0.72 | ALDH1A1 (0.50) | CDK1TPI1CASP6EPHX2CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107987028-B | Preparation method of drug intermediate for treating type II diabetes | 张吉新 | 2018-12-18 | — | — | CN | claimed |
| CN-107987028-A | Preparation method of drug intermediate for treating type II diabetes | 陈洪芳 | 2018-05-04 | — | — | CN | claimed |
| CN-111574463-B | Rivastigmine intermediate compound IV | 鲁南制药集团股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-111574520-B | Riagliptin intermediate compound V | 鲁南制药集团股份有限公司 | 2022-08-26 | — | — | CN | disclosed |
| CN-110997675-B | Novel substituted xanthine derivatives | 勃林格殷格翰国际公司 | 2022-06-07 | — | — | CN | disclosed |
| EP-3652176-B1 | SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2021-12-15 | — | — | EP | disclosed |
| EP-3652176-B1 | SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2021-12-15 | — | — | EP | disclosed |
| CN-111574520-A | Riagliptin intermediate compound V | 鲁南制药集团股份有限公司 | 2020-08-25 | — | — | CN | disclosed |
| CN-111574463-A | Riagliptin intermediate compound IV | 鲁南制药集团股份有限公司 | 2020-08-25 | — | — | CN | disclosed |
| EP-3652176-A1 | NOVEL SUBSTITUTED XANTHINE DERIVATIVES | Boehringer Ingelheim International GmbH (DE) | 2020-05-20 | — | — | EP | disclosed |
| CN-110997675-A | Novel substituted xanthine derivatives | 勃林格殷格翰国际公司 | 2020-04-10 | — | — | CN | disclosed |
| WO-2004106337-A1 | XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-6825349-B2 | PURINE DERIVATIVES FOR TREATMENT OF GASTROINTESTINAL DISORDERS, IMMUNOLOGICAL DISORDERS, NEUROLOGICAL DISORDERS | CV THERAPEUTICS INC. | 2004-11-30 | — | — | US | disclosed |
| US-20040176399-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2004-09-09 | — | — | US | disclosed |
| EP-1444233-A2 | A 2B? ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040152027-A1 | Toning agents for use in thermographic recording materials | AGFA-GEVAERT (BE) | 2004-08-05 | — | — | US | disclosed |
| EP-1435298-A2 | Toning agents for use in thermographic and photothermographic recording materials | Agfa-Gevaert (BE) | 2004-07-07 | — | — | EP | disclosed |
| US-20030229106-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2003-12-11 | — | — | US | disclosed |
| US-20030139428-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2003-07-24 | — | — | US | disclosed |
| WO-2003042214-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139428-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | CDK1 2989/4885TPI1 2941/4885CASP6 3479/4885 |
| US-20030229106-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | CDK1 2989/4885TPI1 2941/4885CASP6 3479/4885 |
| US-20040176399-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | CDK1 2394/4885TPI1 2383/4885CASP6 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.